Drägerwerk (DRW3) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
6 Jan, 2026Executive summary
Profitability improved in 2024, with EBIT up 17% to EUR 194 million, supported by operating improvements and one-off effects totaling around EUR 22 million.
Net sales remained stable at EUR 3.4 billion (+0.5% currency-adjusted), matching the prior year despite a sharp decline in China sales.
Free cash flow increased to EUR 124 million, slightly above the prior year.
Order intake exceeded the high level of the prior year, reflecting sustained demand for core technologies, with declines in China offset by growth elsewhere.
Dividend payout set at 30% of net profit, with higher dividends per share proposed for 2024.
Financial highlights
Net sales stable year-over-year at EUR 3.4 billion; currency-adjusted sales grew 0.5%.
EBIT rose 17% to EUR 194 million, with EBIT margin up from 4.9% to 5.8%.
Gross profit margin increased by 1.6 percentage points to 44.9%.
Net financial debt improved to EUR 165 million, with leverage at 0.5.
Equity ratio at 49.7%, up 4.1 percentage points.
Outlook and guidance
For 2025, currency-adjusted net sales are expected to grow 1%-5%, with an EBIT margin between 3.5%-6.5%.
Both divisions are expected to contribute to sales growth and positive EBIT.
Stabilization and slight growth anticipated in China, but not a return to 2023 volumes.
Ongoing commitment to increase EBIT margin by 1 percentage point per year on average.
Latest events from Drägerwerk
- Record sales, higher EBIT, and increased dividends marked robust growth in 2025.DRW3
Q4 202524 Mar 2026 - 2025 sales reached €3.5bn with rising profitability and a focus on innovation and sustainability.DRW3
Investor presentation24 Mar 2026 - EBIT and net profit rose despite lower sales, led by safety division growth and one-off gains.DRW3
Q2 20242 Feb 2026 - Safety division growth and one-off gains drive higher earnings despite medical segment decline.DRW3
Q3 202418 Jan 2026 - Order intake hit a five-year Q1 high, but earnings fell as medical margins declined.DRW3
Q1 202528 Nov 2025 - Order intake hit a five-year high, but EBIT fell; 2025 guidance confirmed.DRW3
Q2 202516 Nov 2025 - Order intake and net sales surged, driving a raised EBIT margin outlook for 2025.DRW3
Q3 202530 Oct 2025